Warburg-like Metabolic Reprogramming in Endometriosis: From Molecular Mechanisms to Therapeutic Approaches

Kim BS, Bosung Kim, Bo-Sung Kim, Yoon S, Seyeong Yoon, Mi-Ju Park, Sung‐Jin Bae, Jong Kil Joo, Wonnam Kim, Kim W, Ki‐Tae Ha
Pharmaceuticals (Basel, Switzerland) · 2025 · vol. 18(6) , pp. 813 · doi:10.3390/ph18060813 · PMID:40573210 · PMC12195805 · W4410867391
review OA: gold CC0 ⤵ 7 in-corpus citations
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Endometriotic lesions exhibit cancer-like metabolic reprogramming, including increased glycolysis and altered mitochondrial function, which supports cell survival and proliferation, and this review discusses potential therapeutic strategies targeting these pathways.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-18 · read from full text ⓘ

This review examines how Warburg-like metabolic reprogramming, especially aerobic glycolysis, occurs in endometriosis, integrating evidence from molecular mechanisms such as HIF-1α–driven upregulation of glycolysis-related genes, altered activity of glycolytic enzymes (e.g., HK2, PKM2, LDHA), and links to broader pathways like PI3K/AKT/mTOR. It highlights findings that endometriotic lesions show increased glycolysis with lactic acid production and acidic microenvironment formation, along with reported increases in fatty acid oxidation, glutamine metabolism, and mitochondrial dysfunction/ROS changes, with hypoxia and the peritoneal environment proposed to promote these shifts. A major limitation explicitly acknowledged in the paper is that endometriosis pathogenesis and the precise metabolic drivers remain incompletely elucidated, and the discussed “cancer-like” genetic mutations and metabolic adaptations are multifactorial. This paper is centrally about endometriosis — it focuses on Warburg-like metabolic reprogramming as a mechanistic basis and therapeutic target.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a chronic gynecological disorder characterized by the presence of endometrial-like tissue outside the uterus, leading to inflammation, pain, and infertility. Emerging evidence indicates that endometriotic lesions exhibit cancer-like properties, including metabolic reprogramming marked by increased glucose uptake, enhanced Warburg's effect, and altered mitochondrial function. These metabolic adaptations support cell survival under hypoxic conditions and contribute to immune evasion and sustained proliferation. This review summarizes current findings on the molecular mechanisms driving metabolic reprogramming in endometriosis, including the roles of mitochondrial dysfunction, hypoxia-inducible factor (HIF) signaling, the PI3K/AKT/mTOR pathway, inflammatory cytokines, and genetic and epigenetic regulators. In addition, we discuss therapeutic strategies targeting glycolytic pathways using both synthetic inhibitors and natural compounds, which represent promising non-hormonal options. Finally, we highlight the need for further preclinical and clinical studies to validate metabolic interventions and improve outcomes for patients with endometriosis.
Full text 29,591 characters · extracted from pmc-nxml · 7 sections · click to expand

Section 2

The Warburg’s effect, first described by German physician and biochemist Otto Warburg in 1923, describes the metabolic reprogramming of cancer cells in which glucose metabolism is switched from oxidative phosphorylation to aerobic glycolysis, even when sufficient oxygen is present [ 12 ]. Normal cells produce ATP mainly through mitochondrial oxidative phosphorylation, while cancer cells prefer glycolysis and convert pyruvate to lactic acid without entering the tricarboxylic acid (TCA) cycle. This phenomenon provides a number of benefits that promote tumor growth, including rapid production of ATP, availability for biosynthetic building blocks, and adaptation to hypoxic environments [ 13 ]. It was selected as one of the 10 hallmarks of cancer in Douglas Hanahan’s landmark article “Hallmarks of Cancer: The Next Generation” in 2011 [ 14 ]. As illustrated in Figure 1 , the Warburg’s effect is facilitated at the molecular level by the upregulation of key glycolytic enzymes and the activation of oncogenic signaling pathways. Many cancer cells overexpress hexokinase 2 (HK2), which catalyzes the first step of glycolysis by phosphorylating glucose and trapping it in the cell [ 15 ]. Another key regulator is pyruvate kinase M2 (PKM2), which is an isozyme of the less active pyruvate kinase that exists in a dimeric form in cancer cells [ 16 ]. This altered enzyme activity slows down the conversion of phosphoenolpyruvic acid to pyruvic acid, resulting in the accumulation of intermediates that serve as precursors for anabolic pathways involved in nucleotide, amino acid, and lipid biosynthesis. In addition, increased expression of lactate dehydrogenase A (LDHA) promotes the conversion of pyruvate to lactate, facilitating a continuous flow of glycolysis by regenerating NAD⁺. The Warburg’s effect is closely related to tumor-promoting signaling pathways that regulate metabolism [ 17 ]. An essential transcription factor, hypoxia-inducible factor-1α (HIF-1α) is stabilized in hypoxic environments but is upregulated in many cancers regardless of oxygen availability. HIF-1α induces the expression of various glycolysis-related proteins, including glucose transporters (GLUT1 and GLUT3), and pyruvate dehydrogenase kinase 1 (PDK1) and 3 (PDK3). PDK inhibits the activity of pyruvate dehydrogenase (PDH), thereby preventing pyruvate from being converted to acetyl-CoA and entering the TCA cycle. Another important signaling cascade is the PI3K/AKT/mTOR pathway [ 18 ]. This pathway upregulates GLUT1 and HK2 to enhance glucose uptake and glycolysis while inducing cell survival and proliferation. Furthermore, the oncogene MYC plays an important role in enhancing the metabolic reprogramming of cancer cells by activating the production of glycolytic enzymes and mitochondrial biogenesis [ 19 ]. The Warburg’s effect is caused by both active oncogenes and the suppression of tumor suppressor genes. The tumor suppressor gene p53 is frequently mutated in cancer and plays an important role in metabolic regulation [ 20 , 21 ]. Wild-type p53 negatively regulates glycolysis by inducing TP53-induced glycolysis and apoptosis regulator (TIGAR), which lowers the level of fructose-2,6-phosphate, a key activator of phosphofructokinase-1 (PFK1) [ 22 ]. p53 also enhances mitochondrial respiration by promoting the expression of cytochrome c oxidase 2 (SCO 2 ), an important component of the electron transport chain [ 23 ]. When the p53 function is lost in cancer cells, these constraints disappear, allowing glycolysis to proceed unchecked and metabolic adaptation to be further enhanced. The Warburg’s effect is often related to mitochondrial dysfunction, although cancer cells do not completely abandon oxidative phosphorylation [ 24 ]. Instead, many tumors exhibit metabolic plasticity, utilizing both glycolysis and mitochondrial metabolism, depending on the environmental conditions [ 25 ]. This flexibility allows cancer cells to survive in fluctuating oxygen levels and nutrient availability. Also, glutamine metabolism is often increased in tumors, supplying α-ketoglutarate to the TCA cycle and supporting the biosynthesis pathways necessary for rapid proliferation [ 26 ]. The interplay between these processes and alternative metabolic pathways highlights the complexity of cancer metabolism that extends well beyond energy production to include cell signaling, redox balance, and immune evasion. Metabolic reprogramming observed in cancer cells has a significant impact on tumor progression. Increased glucose uptake and lactate production promote invasion and metastasis while contributing to the formation of an acidic microenvironment that suppresses immune cell activity [ 27 , 28 ]. In addition, the conversion to aerobic glycolysis enables the rapid production of macromolecules required for cell division, which is beneficial for cancer cell growth [ 29 ]. Moreover, it can produce ATP quickly without the increase in reactive oxygen species (ROS) that inevitably occurs in mitochondrial respiration using oxygen. The ability of cancer cells to re-adjust their metabolism as described above enables them to resist apoptosis and evade immune surveillance, which increases the complexity of treatment strategies by causing resistance not only to conventional chemotherapeutics but also immunotherapies. Understanding the molecular mechanisms underlying the Warburg’s effect can provide valuable insights into the metabolic vulnerability of cancer cells. Aerobic glycolysis is a hallmark of tumor metabolism; however, the extensive metabolic network that supports tumor growth is highly dynamic, influenced by genetic mutations, tumor microenvironmental factors, and immune interactions. Unraveling these complex metabolic dependencies presents potential opportunities for cancer therapy.

Section 3

Recent research has highlighted metabolic reprogramming as a key factor in the pathophysiology of endometriosis, influencing cell survival, proliferation, and immune evasion [ 10 , 30 , 31 , 32 ]. In normal endometrial cells, the metabolic process is tightly regulated by the hormonal cycle. However, ectopically located endometriotic cells in the peritoneal cavity exhibit distinct metabolic alterations that distinguish them from normal cells ( Figure 2 ) [ 33 , 34 ]. A characteristic of this change is the shift to aerobic glycolysis, commonly known as the Warburg’s effect, in which the pathway is re-routed so that glucose metabolism prefers glycolysis rather than oxidative phosphorylation (OXPHOS). Increases in lactic acid production lead to an acidic microenvironment that promotes inflammation and immune evasion. In addition, fatty acid oxidation is increased in endometriotic lesions, providing an alternative energy source to maintain cell survival under stress conditions [ 35 ]. Glutamine metabolism has also been reported to contribute to the production of NADPH, which is essential for cell proliferation, and to the biosynthesis process [ 30 , 36 ]. Hypoxia, a common feature of endometriotic lesions, plays an important role in promoting these metabolic changes [ 37 , 38 ]. Since the intraperitoneal cavity, where endometriosis develops, has a lower oxygen concentration than normal tissues, HIF-1α is activated under hypoxic conditions, which, in turn, inhibits mitochondrial oxidative phosphorylation and enhances gene expression of the glycolysis pathway. As a result, mitochondrial dysfunction—characterized by decreased efficiency of the electron transport chain, increased ROS production, and mitochondrial DNA mutations—is frequently observed in endometriosis cells. These changes contribute to the cellular stress response, further enhancing inflammation and disease progression [ 39 ]. Initially, this change was understood to be simply an adaptation to the intraperitoneal environment with a shortage of oxygen; however, a series of studies conducted in the late 2010s showed that cancer-like genetic mutations appear in endometrial tissue and accumulate further in ectopic endometrial tissue [ 40 , 41 ]. Therefore, it has been proposed that the accumulation of these genetic mutations may lead to metabolic abnormalities in endometriotic cells. Metabolic reprogramming in endometriosis, as represented in Figure 2 , represents a multifaceted process involving increased glycolysis, enhanced fatty acid oxidation, and mitochondrial dysfunction, all contributing to the persistence and progression of the disease [ 42 ]. Understanding these metabolic adaptations may open new avenues for potential therapeutic interventions targeting specific metabolic pathways to alleviate the burden of endometriosis.

Section 4

Hypoxia is a characteristic feature of endometriotic lesions, which is caused by the nature of the peritoneal environment, insufficient vascularization of ectopic endometrial tissue, and high metabolic demand [ 37 ]. Under these conditions, HIF-1α is stabilized and translocated to the nucleus, likely avoiding proteasome degradation. HIF-1α activates the transcription of genes essential for survival and glycolysis under oxygen deprivation. McKinnon et al. explained that this activation increases the expression of glucose transporters such as GLUT1 and GLUT4, enabling a continuous supply of glucose ( Figure 3 ) [ 43 ]. HIF-1α also increases the expression of important glycolytic enzymes, including HK2, PFK, PDK1, and LDHA [ 44 ]. Several researchers have further emphasized that TGF-β1 and hypoxia increase the activity of HIF-1α, leading to the enhancement of the process [ 10 , 45 , 46 , 47 ]. In addition, hypoxia-induced stabilization of HIF-2α and its interaction with the VEGF pathway promote angiogenesis and establish a positive feedback loop that exacerbates hypoxic conditions and enhances pathological processes such as neovascularization and tissue invasion [ 48 , 49 ]. Recently, non-canonical mechanisms have been proposed in which HIF is activated by metabolic products such as lactate and succinate even when the tissue is not actually hypoxic, indicating that these mechanisms may also affect endometriosis [ 50 ]. Prior research showed that the buildup of ROS completes the pathological cycle and supports the growth of the lesion by stabilizing HIF-1α and promoting inflammation [ 51 , 52 , 53 ]. In particular, oxidative stress and reactive oxygen species (ROS) production are both a consequence and a driving force of glycolytic reprogramming. Accumulated ROS can activate key signaling pathways such as HIF-1α and NF-κB, which, in turn, enhance the expression of glycolytic enzymes and glucose transporters, thereby reinforcing the glycolytic phenotype [ 54 , 55 ]. Conversely, the shift toward aerobic glycolysis reduces mitochondrial oxidative phosphorylation, which can lead to electron leakage and further ROS generation [ 56 ]. This bidirectional relationship contributes to a self-sustaining cycle that supports the survival and proliferation of endometriotic cells under hypoxic conditions. A number of studies have shown that the PI3K/AKT/mTOR pathway is deeply involved in the metabolic reprogramming of endometriosis [ 57 , 58 ]. As presented in Figure 3 , activation of PI3K induces downstream phosphorylation of AKT and activation of mTORC1, which, in turn, enhances HIF1A expression and glycolytic enzyme activity. The mTORC1 complex not only promotes glycolysis but also protein synthesis, lipid biosynthesis, and nucleotide production to meet the metabolic demands of rapidly dividing cells. Crosstalk with AMP-activated protein kinase (AMPK) and feedback regulation through Tuberous sclerosis complex 2 (TSC2) ensure metabolic balance, whereas persistent mTOR activation in endometriotic lesions results in uncontrolled glycolysis and cell proliferation [ 59 ]. Additional evidence from protein and transcriptome studies demonstrates that phosphatase and tensin homolog deleted on chromosome 10 (PTEN) loss and AKT hyperactivation lead to metabolic rearrangements that contribute to extracellular matrix remodeling, angiogenesis, and invasiveness [ 60 , 61 , 62 ]. Furthermore, PIK3CA may be involved in encouraging the glycolysis of endometriosis, because it is one of the cancer-like mutations discovered in endometriotic tissue [ 63 ]. Chronic inflammation is a distinctive feature of endometriosis, and inflammatory cytokines directly affect cellular metabolism. Young et al. (2014, 2016) demonstrated that transforming growth factor-β1 (TGF-β1) regulates inhibitor of DNA-binding 2 (ID2), which, in turn, releases HIF-1α from inhibition and enhances the process [ 10 , 64 ]. In addition, cytokines such as interleukin (IL)-6, IL-1β, and tumor necrosis factor-α (TNF-α) activate the nuclear factor kappa B (NF-κB) and signal transducer and activator of transcription 3 (STAT3) pathways, which upregulate glycolytic enzymes and downregulate mitochondrial oxidative phosphorylation ( Figure 3 ) [ 65 , 66 ]. Several studies have confirmed that inflammatory cytokines promote glucose uptake and lactate production in endometriotic cells [ 67 , 68 ]. The studies also revealed that chemokines such as CXCL12 and its receptor CXCR4 play an important role in regulating glucose metabolism and cell migration [ 69 , 70 ]. Furthermore, several investigations have provided transcriptomic and proteomic evidence that inflammatory signals induce metabolic adaptation by inhibiting mitochondrial oxidative phosphorylation while simultaneously upregulating certain mitochondrial and glycolytic enzymes involved in alternative metabolic routes [ 71 , 72 ]. This seemingly paradoxical regulation reflects a cellular compensatory mechanism; while mitochondrial respiration is suppressed due to hypoxia or inflammation-induced damage, cells increase the expression of enzymes related to mitochondrial biogenesis, antioxidant defense (e.g., SOD2), or metabolic flexibility (e.g., citrate synthase and PDK1) to adapt to stress and sustain energy production through glycolysis and other non-canonical pathways. Thus, the upregulation of these enzymes does not necessarily indicate enhanced mitochondrial activity but rather a shift in metabolic programming to cope with mitochondrial dysfunction [ 73 , 74 , 75 ]. Epigenetic regulation and genetic predisposition contribute significantly to metabolic rearrangement in endometriosis. According to whole-genome studies and epigenomic profiling, endometriosis lesions adapt through stable genetic and epigenetic modifications [ 76 , 77 , 78 ]. Genomic modifications such as single-nucleotide polymorphisms in metabolic genes and mutations in regulators of the PI3K/AKT/mTOR pathway can induce metabolic reprogramming. Several studies have emphasized that DNA methylation changes, histone modifications, and regulation by microRNAs such as miR-21, miR-210, and miR-145 affect the pathways and mitochondrial function ( Figure 3 ) [ 79 , 80 , 81 ]. In addition to miRNAs, it has been found that some lncRNAs, such as H19 and MALAT1, and some circRNAs play an important role in the regulation of glycolysis [ 82 , 83 , 84 , 85 ]. Wen et al. [ 86 ] highlighted key lncRNAs that promote the expression of glycolytic enzymes and affect glucose metabolism in endometriotic cells. Mitochondrial dysfunction is an important factor in the metabolic reprogramming of endometriotic cells. Several researchers have demonstrated that the reduction of prohibitin (PHB) and mitochondrial dysfunction increases the dependence on metabolic reprogramming ( Figure 3 ) [ 87 , 88 , 89 ]. In addition, proteomic changes were identified that are consistent with mitochondrial dysfunction. For instance, mitochondrial dysfunction is associated with the downregulated expression of key enzymes in the oxidative phosphorylation pathway [ 90 , 91 , 92 ]. The increase in ROS generated by dysfunctional mitochondria contributes to genomic instability and chronic inflammation. Moreover, mitochondrial dysfunction has been linked to endometriotic cell proliferation and invasion of the surrounding tissues through ROS-stabilized HIF-1α [ 93 , 94 ]. Angiogenesis and remodeling of the extracellular matrix (ECM) are closely related to metabolic changes ( Figure 3 ). Increased lactate production and secretion promote VEGF expression and neovascularization [ 95 , 96 ]. Several studies have reported that increased matrix metalloproteinases (MMPs), by the glycolysis signal, allows the invasion into neighboring tissues [ 97 , 98 ].

Section 5

As shown in Table 1 and illustrated in Figure 4 , ongoing research on glycolysis inhibitors for endometriosis is being conducted using various compounds, depending on the molecular target. A brief comparison of key candidate compounds is summarized in Table 2 . The PDK family has emerged as the most important target, and dicarboxylate (DCA), a drug that was long ago approved by the FDA as an inhibitor of lactic acidosis, is the most extensively studied candidate. In previous preclinical and early clinical studies (Horne et al. 2019; Lee HC et al. 2019; Leow HW et al. 2021), DCA was shown to restore mitochondrial function by inhibiting PDK1, reduce lactic acid production, and alleviate endometriosis-related pain [ 99 , 100 , 101 ]. Similarly, Caesalpinia sappan extract was shown to inhibit the glycolytic activity of endometriotic cells and induce apoptosis by reducing the expression of PDK1 and PDK3 [ 102 ]. However, it should be noted that DCA requires relatively high concentrations (in the millimolar range) to exert its effects, which raises concerns about specificity and potential off-target effects. Despite this limitation, its progression to early-phase clinical trials highlights its significance in the field and underscores the need for further research into more potent and selective metabolic inhibitors. Moreover, enzymes like LDHA and PKM2 are garnering attention [ 103 ]. LDHA inhibition through shRNA has been shown to suppress glycolysis and promote cell death in endometriotic cells [ 104 ]. In addition, Cho et al. (2022) reported that Prunella vulgaris extract effectively reduces aerobic glycolysis and prevents lesion growth by inhibiting LDHA as the main target and inhibiting the expression of PDK1 and PDK3 at the same time [ 105 ]. They also showed that ursolic acid, a constituent of Prunella vulgaris , effectively inhibits LDHA [ 106 ]. Recently, a number of research groups have been actively conducting research on LDHA inhibitors with anticancer activity, so it is expected that research on these drugs for endometriosis will also be expanded. Research on PKM2 has revealed that inhibiting PKM2 using succinic acid reduces cell viability by inhibiting the corresponding process in endometriosis stromal cells [ 107 ]. Proviral insertion in murine lymphomas 2 (PIM2) kinase has been identified as a key regulator of the expression of glycolysis enzymes such as PKM2 and HK2, while inhibiting PIM2 by treating SMI-4a reduces glycolysis and fibrosis [ 108 , 109 ]. In addition, p21-activated kinase 5 (PAK5) increases the protein stability of PKM2; thus, inhibiting PAK5 with GNE 2661 inhibited glycolysis and growth in endometriosis [ 110 ]. Another notable target is phosphofructokinase/fructose bisphosphatase (PFKFB3), and the inhibitor PFK-015 has been shown to inhibit cell proliferation, migration, and invasion by suppressing the glycolysis process through the inhibition of the enzyme at the cellular and in vivo levels [ 117 ]. Recent studies have confirmed that heat shock factor 1 (HSF1) regulates the expression of PFKFB3 and that the inhibitor KRIBB11 suppresses endometriosis in animal experiments [ 113 , 114 ]. Glucose analog 2-DG inhibits HK2, the most upstream enzyme of the glycolysis pathway. It was verified that 2-DG suppressed the infiltration of differentiated M2 macrophages in the endometriotic lesions [ 121 ]. In the study, it was found that the Mettl3/Trib1/ERK-STAT3 pathway plays an important role [ 116 ]. The involvement of Aurora kinase A (AURKA) and carboxyl terminus of the Hsc70-interacting protein (CHIP) pathways in glycolysis regulation provides new therapeutic targets. Alisertib (AURKA inhibitor) and YL-109 (CHIP agonist) have shown potential for the treatment of endometriosis in animal studies [ 115 , 118 ]. Resveratrol, a natural product found in grapes, has demonstrated inhibitory effects on glycolysis and anti-angiogenesis in animal models when administered alone or in combination with atorvastatin [ 112 ]. Gui-Zhi-Fu-Ling capsules, a traditional Chinese medicine, have also shown a positive effect on endometriosis by inhibiting multiple targets such as TGF-β1, GLUT4, and VEGF [ 111 , 122 ]. However, despite the accumulation of research on the metabolic abnormality of endometriosis, especially aerobic glycolysis, more preclinical and clinical research needs to be carried out. Most animal experiments using molecular targeted inhibitors are still not enough to be considered as accurate preclinical research. To date, the only clinical trial targeting the glycolytic pathway of endometriosis has found that DCA could suppress pain in endometriosis patients. We expect that research on drug development using diverse molecular targets in this field will become increasingly active in the future.

Section 6

Metabolic reprogramming, especially the shift to glycolysis, plays an important role in the persistence and progression of endometriotic lesions. Increased lactate production and altered energy metabolism create an acidic microenvironment that promotes angiogenesis, tissue invasion, and immune evasion [ 119 , 120 ]. These metabolic abnormalities lead to changes in the extracellular matrix composition and the immune cell infiltration. This metabolic state not only helps the survival of ectopic endometrial cells but also promotes chronic inflammation, which increases the severity of symptoms ( Figure 5 ). The continuous metabolic flux can alter the local nerve fiber density and contribute to the development of neuropathic pain [ 10 , 123 ]. In particular, pain is the most critical symptom that reduces the quality of life of patients with endometriosis. In clinical studies, PDK1 inhibitor DCA has been confirmed to contribute to the reduction of pain in endometriosis patients. Inflammatory responses affecting the oocyte, the endometrium, and the hormonal regulation are closely associated with infertility in endometriosis patients [ 124 ]. High lactate levels and oxidative stress can reduce the quality of eggs, interfere with the receptivity of the endometrium, and affect embryo implantation [ 125 ]. Metabolic environment change can disrupt hormonal signaling in reproductive tissues and cause oxidative DNA damage [ 126 , 127 ]. In addition, the accumulation of inflammatory cytokines and neurovascular factors in the active lesion of glycolysis can cause chronic pelvic pain and dysmenorrhea [ 128 ]. The pain pathway is further sensitized by local nerve growth, cytokine release, and metabolic byproducts such as lactic acid and reactive oxygen species. Fibrosis is promoted by altered metabolites, and inflammatory cytokines induce serious complications, including adhesions to the surrounding tissue of endometriosis lesions. Currently, the standard drug treatment for endometriosis, hormonal therapy (e.g., GnRH agonists and oral contraceptives), aims to suppress estrogen-induced proliferation, although it does not directly act on metabolic changes ( Figure 5 ) [ 129 , 130 ]. Recent evidence suggests that the combination of hormonal therapy and metabolic interventions may improve treatment outcomes. For example, mTOR inhibitors and glycolysis inhibitors can improve the effectiveness of standard treatments by addressing the metabolic dependency of endometriosis lesions. Metabolic therapy can help overcome treatment resistance in patients with active metabolic lesions. Furthermore, anti-inflammatory and mitochondrial-targeted therapies can complement existing therapies to reduce recurrence rates and provide more effective symptom relief. However, it is worth noting that most of the supporting studies for these metabolic interventions are limited to preclinical research, with only one small-scale clinical trial conducted to date. As such, the current evidence base remains insufficient, underscoring the need for further clinical investigations to validate these promising therapeutic strategies.

Intro

Endometriosis is a chronic gynecological condition characterized by the presence of endometrial-like tissue outside the uterus, mainly in the ovaries, fallopian tubes, and peritoneum [ 1 ]. This ectopic endometrium undergoes cyclic changes similar to the normal endometrium, causing inflammation, fibrosis, and adhesion formation. Endometriosis is estimated to affect 10–15% of reproductive age women with severe health problems, such as chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility [ 2 , 3 ]. Despite its high prevalence, the precise pathogenesis of this disease has not yet been fully elucidated [ 4 , 5 ]. Several factors, including hormonal imbalance, immune dysfunction, genetic predisposition, and environmental influences, contribute to the development and progression of this disease. Due to the non-specific symptoms and limited public recognition, many patients experience delays in diagnosis and treatment. Current treatment options involve surgical and hormonal therapies, which focus on symptom management rather than fundamental treatment [ 6 , 7 ]. Since hormone therapy is often accompanied by serious side effects, the need for non-hormonal treatments has been in the spotlight [ 8 ]. Endometriosis manifests several cancer-like characteristics, including local invasion, distant metastasis, apoptotic cell death resistance, and immune evasion [ 9 ]. Recent evidence shed light on shared pathological mechanisms of the two diseases; a process known as metabolic reprogramming is one of the key mechanisms. Specifically, endometriotic lesions also exhibit a metabolic profile similar to the Warburg’s effect in cancer cells, which is characterized by increased glucose uptake, enhanced glycolysis, and altered mitochondrial function [ 10 ]. The metabolic shift to aerobic glycolysis promotes energy production and the biosynthesis of cellular building blocks, which helps the survival and proliferation of ectopic endometrial cells [ 11 ]. The Warburg’s effect enables migrated endometrial cells to adapt to the low-oxygen environment of the peritoneal cavity, avoiding cell death and maintaining an inflammatory condition. Therefore, targeting glycolytic metabolism—a key pathway underlying the Warburg’s effect—emerges as a promising therapeutic strategy for endometriosis. This review provides a detailed overview of the molecular mechanisms underlying aerobic glycolysis in endometriosis, along with therapeutic approaches, including metabolic inhibitors and dietary interventions. A comprehensive understanding of these metabolic features is expected to facilitate the development of more effective treatment strategies and ultimately improve clinical outcomes.

Conclusions

Warburg-like metabolic reprogramming is one of the fundamental features of endometriosis, contributing to lesion survival, progression, and symptom severity. Under hypoxic and inflammatory conditions, the transition to this process promotes angiogenesis, immune evasion, and tissue invasion while also exacerbating pain and infertility. Understanding these metabolic changes has led to new treatment methods that target metabolic vulnerabilities in endometriotic lesions, as well as hormonal pathways. It is expected that metabolic inhibitors, when combined with existing treatments, will enhance treatment efficacy, reduce recurrence, and improve patients’ quality of life. As research continues, we believe that metabolic profiling and precision medicine approaches will play an increasingly important role in the clinical management of endometriosis. Future molecular studies of the Warburg’s effect in endometriosis should focus on several key areas. First, the precise regulatory mechanisms of HIF-1α and HIF-2α activation under fluctuating hypoxic conditions in the endometriotic microenvironment should be elucidated. It is important to understand how these factors interact with inflammatory cytokines and hormonal signaling. Second, the role of mitochondrial dynamics, including mitophagy and biogenesis, in glycolytic reprogramming maintenance requires further investigation. Third, studies should explore the post-transcriptional regulation of glycolytic enzymes and transporters, with a focus on non-coding RNAs such as lncRNAs and circRNAs. Fourth, the development of advanced metabolomics and single-cell transcriptomics technologies will enable the identification of subpopulations of endometriotic cells with distinct metabolic phenotypes, which will allow for personalized treatment. Finally, large-scale translational studies are needed to validate the efficacy of metabolic biomarkers for early diagnosis, treatment monitoring, and prognosis prediction. This area of research will help to deepen our understanding of metabolic changes and develop new therapeutic strategies for endometriosis. Future studies will likely explore the use of combination metabolic inhibitors and non-hormonal therapies in patient populations that do not respond to or are contraindicated for hormonal therapy. Clinical trials focused on metabolic regulation are poised to change the landscape of endometriosis treatment and have the potential to improve long-term outcomes and quality of life for affected women.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisinfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (11)

Source provenance

europepmc
last seen: 2026-08-05T06:13:34.187606+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pmc
last seen: 2026-05-13T20:22:03.195721+00:00
pubmed
last seen: 2026-08-05T06:10:12.010889+00:00
License: CC0 · commercial use OK